Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

Testosterone, terfenadine, midazolam, and nifedipine, four commonly used substrates for human cytochrome P-450 3A4 (CYP3A4), were studied in pairs in human liver microsomes and in microsomes from cells containing recombinant human CYP3A4 and P-450 reductase, to investigate in vitro substrate-substrate interaction with CYP3A4. The interaction patterns between compounds with CYP3A4 were found to be substrate-dependent. Mutual inhibition, partial inhibition, and activation were observed in the testosterone-terfenadine, testosterone-midazolam, or terfenadine-midazolam interactions. However, the most unusual result was the interaction between testosterone and nifedipine. Although nifedipine inhibited testosterone 6beta-hydroxylation in a concentration-dependent manner, testosterone did not inhibit nifedipine oxidation. Furthermore, the effect of testosterone and 7,8-benzoflavone on midazolam 1'-hydroxylation and 4-hydroxylation demonstrated different regiospecificities. These results may be explained by a model in which multiple substrates or ligands can bind concurrently to the active site of a single CYP3A4 molecule. However, the contribution of separate allosteric sites and conformational heterogeneity to the atypical kinetics of CYP3A4 can not be ruled out in this model.

[1]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[2]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[4]  W. Pryor Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[5]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[6]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[7]  A. Y. Lu,et al.  Role of pharmacokinetics and metabolism in drug discovery and development. , 1997, Pharmacological reviews.

[8]  F. Guengerich,et al.  Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.

[9]  C. W. Fisher,et al.  Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[11]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[12]  H. Yamazaki,et al.  Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. , 1996, Archives of biochemistry and biophysics.

[13]  Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[15]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Venkatesan Pharmacokinetic Drug Interactions with Rifampicin , 1992, Clinical pharmacokinetics.

[17]  A. D. Rodrigues,et al.  In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[18]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[19]  T. Rushmore,et al.  INHIBITORY ANTI-CYP 3 A 4 PEPTIDE ANTIBODY : MAPPING OF INHIBITORY EPITOPE AND SPECIFICITY TOWARD OTHER CYP 3 A ISOFORMS , 1999 .

[20]  I. H. Segel Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[21]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[22]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[23]  F. Guengerich,et al.  Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. , 1994, Archives of biochemistry and biophysics.

[24]  C. W. Fisher,et al.  The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. , 1995, Archives of biochemistry and biophysics.

[25]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[26]  A. Y. Lu,et al.  Chapter 30. Inhibition of Cytochrome P-450 and Implications in Drug Development , 1997 .

[27]  A. Y. Lu,et al.  Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. Weintraub,et al.  Drug Interactions with Grapefruit Juice , 1997, Clinical pharmacokinetics.

[29]  S. Imaoka,et al.  Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. , 1992, Biochemistry.

[30]  F. Guengerich Characterization of human cytochrome P450 enzymes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[32]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[33]  M H Tarbit,et al.  Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  A. P. Koley,et al.  CO Binding Kinetics of Human Cytochrome P450 3A4 , 1995, Journal of Biological Chemistry.

[35]  T. Kost,et al.  CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. , 1995, Archives of biochemistry and biophysics.

[36]  T. Kamataki,et al.  P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.

[37]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[38]  A. P. Koley,et al.  Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.

[39]  H. Yamazaki,et al.  Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes , 1996 .

[40]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[41]  M. Franklin Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes , 1977 .